SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is announcing the next milestone achievement in their plan to actively and aggressively register a pipeline of cannabis products for healthcare professionals and pharmacies.
For the first time, twelve of Medical Marijuana, Inc.’s products received overseas registration and approval as international medicinal products. This opens the ability for pharmacies and healthcare providers to distribute cannabis products to patients.
“HempMeds is proud to announce that 12 of our RSHO products have received certificates of approval ‘Registro de Medicamentos’ issued by Departmento de Salud (Department of Health),” states Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “Our distribution partners have many inroads within the local over-the-counter and pharmacy space, thus we look forward to supporting their efforts with education and future studies regarding the benefits of natural botanical hemp-based CBD products.”
The approval opens up the ability for the company to have marketing companies, healthcare providers, pharmaceutical companies and pharmacies to sell these product lines.
Medical Marijuana, Inc.’s dedication to actively and aggressively receive product registration, develop its product pipeline and perform proper pre-clinical work.
About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT: For further information, please contact: Public Relations contact: Andrew Hard Chief Executive Officer CMW Media P. 858-380-5478 email@example.com www.cmwmedia.com Corporate contact: Medical Marijuana, Inc. Toll Free: 888-OTC-MJNA (888-682-6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc Investor Relations: GH Investment Advisors 550 West "C" Street, Ste. 2040 San Diego, CA 92101 Nick Massalas Office: (858) 264-6500 Toll Free: (877) 964-6463 firstname.lastname@example.org